The prognostic value of PSA kinetics in untreated men with prostate cancer

The question of whether PSA kinetics (e.g., PSA doubling time and PSA velocity) can be used to accurately project risk for prostate cancer progression and mortality is still not definitively known (although it is much debated). … READ MORE …

Are changes in PSA kinetics potentially indicative of metastasis-free survival?

Researchers at Johns Hopkins have provided data to support the hypothesis that, in men being treated with novel, non-hormonal agents for non-metastatic, non-castrate, biochemically recurrent prostate cancer after first-line therapy, changes in PSA kinetics may be indicative of metastasis-free survival. … READ MORE …

PSA kinetics do not predict pathology in men on active surveillance

The role of PSA kinetics (i.e., PSA doubling time and PSA velocity) in the early diagnosis of prostate cancer and in the monitoring of patients on active surveillance protocols has been controversial. We now have some more definitive data. … READ MORE …

What’s in the April issue of AUA News?

There are several articles that may be of interest to readers in the April issue of the AUA News, which is now available on line. … READ MORE …